CN103655649A - Production technology for concentrating raw material extract of traditional Chinese medicine preparation of anti-inflammation and cholagogic tablet - Google Patents
Production technology for concentrating raw material extract of traditional Chinese medicine preparation of anti-inflammation and cholagogic tablet Download PDFInfo
- Publication number
- CN103655649A CN103655649A CN201310692048.9A CN201310692048A CN103655649A CN 103655649 A CN103655649 A CN 103655649A CN 201310692048 A CN201310692048 A CN 201310692048A CN 103655649 A CN103655649 A CN 103655649A
- Authority
- CN
- China
- Prior art keywords
- concentration
- concentrated
- raw material
- membrane
- production technology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
The invention relates to a production technology for concentrating a raw material extract for a traditional Chinese medicine preparation of an anti-inflammation and cholagogic tablet. According to the production technology, separating membranes with the selective active pharmaceutical ingredient retaining performance are used for performing membrane separation and concentration on the raw material extract under pressure, types of the separating membranes include ultrafiltration membranes, nanofiltration membranes and reverse osmosis membranes, and materials of the separating membranes include cellulose membranes, polysulfone membranes, polyamide membranes, ceramic membranes and the like. During membrane separation and concentration, the concentration of the extract is in a range of 0.1%-16% by the solid content, the operating temperature is in a range of 3 DEG C-80 DEG C, and the operating pressure is in a range of 0.1 MPa-6.0 MPa; and factors such as the extract concentration, the operating temperature, the operating pressure and the like can influence the permeation flux, and the permeation flux can be increased by reduction of the extract concentration, increase of the temperature and increase of the pressure. According to the production technology, heating is not required, no phase change occurs, the biological activity is not damaged, energy conservation and consumption reduction can be realized, the medicine quality can be improved, the production efficiency can be improved, and the production cost can be remarkably reduced.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicine pharmacy, relate to a kind of Chinese medicine preparation XIAOYAN LIDAN PIAN, when producing, raw material extracting solution is carried out to concentrated new process.
Background technology
Chinese medicine preparation XIAOYAN LIDAN PIAN is the Chinese patent medicine that is usually used in clinically treating acute cholecystitis, biliary tract inflammation; Its drug standard records in one of < < Pharmacopoeia of People's Republic of China > > version in 2010, according to the method for making of stipulating in this standard, pharmacy corporation carries out the concentrated common process method of Chinese medicine extraction: Herba Andrographis and Ramulus Et Folium Picrasmae medical material extract secondary with 10～12 times of amount 80%～85% alcohol heating reflux, each 2 hours, extracting solution reclaimed ethanol and is condensed into extractum; Herba Rabdosiae Lophanthoidis adds 12～16 times of amount drinking waters to decoct secondary, and each 2 hours, it was 1.20～1.25 (55～60 ℃) that extracting solution is concentrated into relative density, adds appropriate high concentration ethanol, stirs evenly, standing, filter, and filtrate recycling ethanol, and be condensed into extractum.
The common process method that Chinese medicine preparation anti-inflammatory and choleretic tablet raw material extracting solution is concentrated, Chinese medicine alcohol extract is to adopt vacuum distilling or air-distillation equipment, in the mode of heating evaporation, carry out ethanol recovery and medicinal liquid is concentrated, Chinese medicine aqueous extract be also adopt economic benefits and social benefits or Multi-effect concentration equipment, in the mode of heating evaporation, to carry out medicinal liquid concentrated.Because the concentration of raw material extracting solution is conventionally lower, solid content is generally between 0.1%～16%, and therefore in heating evaporation mode, to carry out concentrated stage energy consumption very large follow-up; And because medicinal liquid is heated for a long time, can cause the degraded of effective medicinal components to destroy, and also there will be a large amount of extractum to stick to the phenomenon of inner tank wall and inner-walls of duct simultaneously, even often there is extractum to be burnt the situation of degeneration; Traditional Chinese medicine extraction liquid method for concentration exists that energy consumption is high, yield is low, it is consuming time compared with the problem such as long, solvent loss is large, extract quality is lower to produce, and production efficiency is low, drug quality is unstable, production cost is high.
Summary of the invention
The object of the present invention is to provide the concentrated production technology of a kind of Chinese medicine preparation anti-inflammatory and choleretic tablet raw material extracting solution.
The invention provides the concentrated production technology of a kind of Chinese medicine preparation anti-inflammatory and choleretic tablet raw material extracting solution, comprise the steps:
S1, raw material alcohol extraction: the Herba Andrographis of same aliquot being mixed with Ramulus Et Folium Picrasmae and use concentration is twice of 80%～85% ethanol heating extraction, each extraction time is 2 hours, to the filtrate of twice filtration being merged, is concentrated after the extracting liquid filtering of each extraction, obtain solid content and be 0.1%～16% alcohol extract, standby;
S2, membrance separation: select the diffusion barrier that medicine activity component is had to a selective retention performance to carry out pre-concentration to the alcohol extract obtaining in S1, wherein, isolated permeate is the alcoholic solution in the alcohol extract in S1, after reclaiming remaining ethanol by vacuum distillation equipment again, pastille concentrated solution after holding back is condensed into thick paste, wherein, operative temperature during membrance separation is 3 ℃～80 ℃; Operating pressure is 0.1MPa～6.0MPa;
S3, raw material water extraction: get with Herba Andrographis and decoct with water secondary with the Herba Rabdosiae Lophanthoidis of aliquot, the decoction liquor that each decoction is obtained is filtered, and by filtrate merge, concentrated, obtain solid content and be 0.1%～16% aqueous extract, standby;
S4, the membrance separation of Herba Rabdosiae Lophanthoidis extracting solution: select diffusion barrier medicine activity component to selective retention performance, by membrane separation plant, aqueous extract is carried out to pre-concentration, wherein, isolated permeate is the water in the aqueous extract in S3, pastille concentrated solution after holding back is transferred to evaporation concentration equipment again, being concentrated into relative density is 1.20～1.25(55～60 ℃) mastic, the ethanol that adds the concentration 60%～70% of 5～8 times of mastic amounts, stir evenly, standing, filter, filtrate recycling ethanol, and be condensed into Herba Rabdosiae Lophanthoidis extractum, wherein, the operative temperature of membrance separation is 3 ℃～80 ℃, operating pressure is 0.1MPa～6.0MPa,
S5, tablet preparation: two kinds of thick pastes in S2 and S4 are merged, mix, are dried, granulation, dry, in flakes, sugar coating or film-coat, obtain in compacting.
Wherein, in S2, alcohol extract is placed in the first membrane module that the first head tank is crossed First Heat Exchanger, the first cartridge filter and is provided with diffusion barrier through device for cleaning pipeline, and permeate is stored in the first permeate storage tank, and pastille concentrated solution is stored in the first concentrated solution holding vessel.
Wherein, in S4, the second membrane module that aqueous extract is placed in the second head tank and crosses the second heat exchanger, the second cartridge filter and be provided with diffusion barrier through device for cleaning pipeline, permeate is stored in the second permeate storage tank, and pastille concentrated solution is stored in the second concentrated solution holding vessel.
Wherein, in step S2 and step S4, diffusion barrier is selected from ultrafilter membrane or NF membrane or reverse osmosis membrane; The material of described diffusion barrier is selected from cellulose membrane or polysulfone membrane or polyamide membrane or ceramic membrane.In view of anti-inflammatory and choleretic tablet raw material extracting solution adopts membrance separation, be for concentrated object, while selecting diffusion barrier specification, this film just need to have larger percolate flux and the higher rejection to medicinal ingredient in raw material extracting solution simultaneously, therefore, the rejection of percolate flux and medical substance composition is to be the bigger the better.The model performance of the molecular weight of the XIAOYAN LIDAN PIAN medical substance composition of recording according to correlational study document and commercially available all kinds of nanofiltration, reverse osmosis product film, and consider medicine Registration regulations and the requirement of drug GMP certification to Chinese medicine enrichment process, percolate flux and investigate film rejection after tested, finally determines that should select specification is the NF membrane of molecular cut off >=200 or reverse osmosis membrane (rejection to bivalence and multivalent salts all need >=90%).
In technical solution of the present invention, at Chinese medicine extraction liquid concentration process, select diffusion barrier medicine activity component to selectivity cutoff performance, utilize the screening separating property of diffusion barrier, under pressure, solvent sees through diffusion barrier, and the active component of Chinese medicine is trapped, thereby reaches concentrated object.During membrane separation concentration, extract concentration is that solid content 0.1%～16%, operative temperature are that 3 ℃～80 ℃, operating pressure are 0.1MPa～6.0MPa; Percolate flux is subject to the impact of the factors such as feed concentration, operative temperature, operating pressure, and reduction feed concentration, raising temperature, raising pressure can improve percolate flux.
In technical solution of the present invention, because the process of membrane separation concentration is a kind of physical process, without any chemical reaction, do not need heating, do not undergo phase transition, can not destroy biological activity, do not change the character of separated object; Dope after membrance concentration can enter into very soon to be received the cream stage, therefore, can farthest reduce medicine activity component and be destroyed, improves drug quality by high temperature degradation.
In technical solution of the present invention, because membrane separation concentration is the screening separating property of utilizing diffusion barrier, complete under pressure the pre-concentration of Chinese medicine extraction liquid, after membrane separation concentration, can get rid of in extracting solution 50%～80% solvent, in membrance separation process, do not use steam, only need to consume electric energy, through measuring and calculating, aspect energy consumption cost, embrane method only accounts for approximately 1/5 of traditional method of evaporating live (open) steam cost, and therefore, technique of the present invention is energy efficient greatly, the steam supply load that reduces boiler, reduces blowdown; Can also improve yield, reduce solvent loss, shorten concentration time, enhance productivity, can significantly reduce production costs, there is economically larger superiority simultaneously.
Accompanying drawing explanation
Fig. 1 is membrane separation concentration principle schematic;
Fig. 2 is the membrane separation concentrated compression apparatus flow chart of S2;
Fig. 3 is the membrane separation concentrated compression apparatus flow chart of S4.
The specific embodiment
Referring to Fig. 1, Fig. 2 and Fig. 3, process of the present invention is the manufacture for Chinese medicine preparation XIAOYAN LIDAN PIAN, enriching stage at raw material extracting solution, raw material extracting solution carries out pre-concentration by membrane separation device, can get rid of most of solvent, the dope after membrane separation concentration (need pass through again vacuum concentrator) can enter soon to be received the cream stage and completes product preparation.In summary of the invention described above, in step S2 and step S4, alcohol extract and aqueous extract be a corresponding head tank, heat exchanger, cartridge filter, the membrane module that is provided with diffusion barrier, permeate storage tank and the concentrated solution holding vessel of being provided with respectively; Alcohol extract and aqueous extract be stored into separately corresponding head tank by pipeline successively by corresponding heat exchanger, cartridge filter and the membrane module that is provided with diffusion barrier, and permeate is stored in corresponding permeate storage tank, pastille concentrated solution is stored in concentrated solution holding vessel.Wherein, the material in permeate storage tank can reuse, when need to clean for membrane module, enters membrane module clean by cartridge filter.
Selection about film:
In view of anti-inflammatory and choleretic tablet raw material extracting solution adopts membrance separation, be for concentrated object, while selecting diffusion barrier specification, this film just need to have larger percolate flux and the higher rejection to medicinal ingredient in raw material extracting solution simultaneously, therefore, the rejection of percolate flux and medical substance composition is to be the bigger the better.The model performance of the molecular weight of the XIAOYAN LIDAN PIAN medical substance composition of recording according to correlational study document and commercially available all kinds of nanofiltration, reverse osmosis product film, and consider medicine Registration regulations and the requirement of drug GMP certification to Chinese medicine enrichment process, percolate flux and investigate film rejection after tested, finally determines that should select specification is the NF membrane of molecular cut off >=200 or reverse osmosis membrane (rejection to bivalence and multivalent salts all need >=90%).
Pure water permeation flux and film rejection determination experiment: because molecular weight minimum in XIAOYAN LIDAN PIAN medical substance composition is also much larger than 200, magnesium sulfate MgSO
4molecular weight be 120, therefore can measure with magnesium sulfate the rejection of film as standard substance; Pure water and 0.2%MgSO
4the permeation flux of solution is as table 1, and as can be seen from Table 1, the flux of pure water increases along with the rising of operating pressure; The permeate of again 0.2% Adlerika being crossed film with pressurization after 30 minutes samples respectively, measures electrical conductivity separately, calculates as follows rejection M (%), the results are shown in Table 2, shows that film rejection meets the requirements, and diffusion barrier is intact without leaking.
M=(1-D
2/D
1)×100%
In formula: D
2for the electrical conductivity of permeate, us/cm;
D
1for the electrical conductivity of Adlerika before mistake film, us/cm.
Table 1:
Table 2:
Production technology of the present invention is in actual mechanical process, and the assay method of parameters is as follows:
(i) the assay method of membrance concentration percolate flux: measure permeate from the permeate outlet of membrane separation device, utilize graduated cylinder and stopwatch, analytical unit obtains the permeate volume excessively of membrance concentration in the time, or measure the required time of expending of membrance concentration permeate that obtains unit volume, then calculate flux J (L/m by following formula
2h):
J=V/(S×T)
In formula: the volume that V is permeate, L;
S is membrane area, m
2;
T is the time, h.
(ii) the measuring method of cycles of concentration: can simultaneously check experimental data with two kinds of measuring methods.
1. direct weighing method: the permeate of crossing to raw material extracting solution, membrance concentration is directly weighed respectively or measures volume, and calculates cycles of concentration N by following formula:
N=G
1/ (G
1-G
2) or N=V
1/ (V
1-V
2)
In formula: G
1for the gross weight of extracting solution before mistake film, kg;
G
2for the gross weight of permeate after mistake film, kg;
V
1for the cumulative volume of extracting solution before mistake film, L;
V
2for the cumulative volume of permeate after mistake film, L.
2. solid content Commutation Law: get raw material extracting solution, cross the concentrated solution after film, dry to constant weight with infrared drying instrument, precise weighing, measures respectively solid content W (%), then by following formula calculating cycles of concentration N:
N=?W
2?/?W
1
In formula: W
1for the solid content of raw material extracting solution, %;
W
2for the solid content of concentrated solution after mistake film, %.
Embodiment 1
XIAOYAN LIDAN PIAN is the raw material prescription with aliquot by Herba Andrographis, Ramulus Et Folium Picrasmae, three kinds of Chinese crude drugs of Herba Rabdosiae Lophanthoidis.Herba Andrographis, 80%～85% ethanol heating extraction secondary for Ramulus Et Folium Picrasmae, each 2 hours, extracting solution is lowered the temperature through plate type heat exchanger, filter, filtrate merges, adopt DK series nanofiltration separation membrane, by membrane separation plant, carry out pre-concentration, during membrance separation, alcohol extract concentration is that solid content 0.6%, operative temperature are that 30 ℃, operating pressure are 1.6MPa, isolated permeate is that the extraction that the solvent (alcoholic solution) in extracting solution can be used for same kind feeds intake, pastille concentrated solution after membrance separation reclaims remaining ethanol by vacuum distillation equipment again, and is condensed into thick paste.Herba Rabdosiae Lophanthoidis decocts with water secondary, decoction liquor is lowered the temperature through plate type heat exchanger, filter, filtrate merges, select DK series nanofiltration separation membrane, by membrane separation plant, carry out pre-concentration, during membrance separation, aqueous extract concentration is solid content 1.3%, operative temperature is 30 ℃, operating pressure is 1.5MPa, isolated permeate is that the solvent (water) in extracting solution can be used as other process waters, pastille concentrated solution after membrance separation is transferred to evaporation concentration equipment again, continuing to be concentrated into relative density is 1.20 (55 ℃), the ethanol that adds appropriate concentration 70%, stir evenly, standing, filter, filtrate recycling ethanol, and be condensed into extractum.Above-mentioned two kinds of thick pastes merge, mix, are dried, granulation, dry, and in flakes, sugar coating or film-coat, obtain in compacting.
Embodiment 2
XIAOYAN LIDAN PIAN is the raw material prescription with aliquot by Herba Andrographis, Ramulus Et Folium Picrasmae, three kinds of Chinese crude drugs of Herba Rabdosiae Lophanthoidis.Herba Andrographis, 80%～85% ethanol heating extraction secondary for Ramulus Et Folium Picrasmae, each 2 hours, extracting solution is lowered the temperature through plate type heat exchanger, filter, filtrate merges, adopt the low pressure reverse osmosis diffusion barrier in reverse osmosis membrane, by membrane separation plant, carry out pre-concentration, during membrance separation, alcohol extract concentration is solid content 0.8%, operative temperature is 36 ℃, operating pressure is 2.6MPa, isolated permeate is that the extraction that the solvent (alcoholic solution) in extracting solution can be used for same kind feeds intake, pastille concentrated solution after membrance separation reclaims remaining ethanol by vacuum distillation equipment again, and be condensed into thick paste.Herba Rabdosiae Lophanthoidis decocts with water secondary, decoction liquor is lowered the temperature through plate type heat exchanger, filter, filtrate merges, select DL series nanofiltration separation membrane, by membrane separation plant, carry out pre-concentration, during membrance separation, aqueous extract concentration is solid content 1.1%, operative temperature is 36 ℃, operating pressure is 2.0MPa, isolated permeate is that the solvent (water) in extracting solution can be used as other process waters, pastille concentrated solution after membrance separation is transferred to evaporation concentration equipment again, continuing to be concentrated into relative density is 1.23 (58 ℃), the ethanol that adds appropriate concentration 70%, stir evenly, standing, filter, filtrate recycling ethanol, and be condensed into extractum.Above-mentioned two kinds of thick pastes merge, mix, are dried, granulation, dry, and in flakes, sugar coating or film-coat, obtain in compacting.
Embodiment 3
XIAOYAN LIDAN PIAN is the raw material prescription with aliquot by Herba Andrographis, Ramulus Et Folium Picrasmae, three kinds of Chinese crude drugs of Herba Rabdosiae Lophanthoidis.Herba Andrographis, 80%～85% ethanol heating extraction secondary for Ramulus Et Folium Picrasmae, each 2 hours, extracting solution is lowered the temperature through plate type heat exchanger, filter, filtrate merges, adopt DL series nanofiltration separation membrane, by membrane separation plant, carry out pre-concentration, during membrance separation, alcohol extract concentration is solid content 1.2%, operative temperature is 23 ℃, operating pressure is 3.0MPa, isolated permeate carries out secondary separation with low-pressure reverse osmosis membrane, permeate feeds intake for the extraction with kind, the pastille dope that twice membrance separation obtains, all by vacuum distillation equipment, reclaim remaining ethanol, and be condensed into thick paste.Herba Rabdosiae Lophanthoidis decocts with water secondary, decoction liquor is lowered the temperature through plate type heat exchanger, filter, filtrate merges, select low pressure reverse osmosis diffusion barrier, by membrane separation plant, carry out pre-concentration, during membrance separation, aqueous extract concentration is solid content 1.5%, operative temperature is 36 ℃, operating pressure is 2.5MPa, isolated permeate is that the solvent (water) in extracting solution can be used as other process waters, pastille concentrated solution after membrance separation is transferred to evaporation concentration equipment again, continuing to be concentrated into relative density is 1.25 (60 ℃), the ethanol that adds appropriate concentration 70%, stir evenly, standing, filter, filtrate recycling ethanol, and be condensed into extractum.Above-mentioned two kinds of thick pastes merge, mix, are dried, granulation, dry, and in flakes, sugar coating or film-coat, obtain in compacting.
Embodiment 4,5,6
The flow process that these three embodiment adopt is consistent with embodiment 2, the different water extraction liquid that is
Solid content and concentrated solution quantity, alcohol extract solid content and cycles of concentration are different, refer to table 3 ~ table 5, wherein, and embodiment 4 and membrance concentration batch 1 corresponding, embodiment 5 and membrance concentration batches 2 corresponding, embodiment 6 and membrance concentration batches 3 corresponding.
The quality index such as the character of XIAOYAN LIDAN PIAN finished medicines, discriminating, content detect, according to the assay method of " XIAOYAN LIDAN PIAN " lower regulation of < < Pharmacopoeia of People's Republic of China > > version in 2010.
The energy consumption comparison of table 3. aqueous extract membrane separation concentration and vacuum-concentrcted
The energy consumption comparison of table 4. alcohol extract membrane separation concentration and vacuum decompression distillation
Table 5. membrane separation concentration contrasts (official method) with vacuum-concentrcted product quality indicator
Compare with traditional heating evaporation concentration technology method, process of the present invention on the one hand can energy efficient, reduce the steam supply load of boiler, reduces production costs; Can also shorten on the other hand the heated time of medicinal liquid when concentrated, avoid effective medicinal components because being heated and degrading for a long time, improve drug quality.The present invention promoting Chinese medicine preparation quality, enhance productivity, save energy and reduce the cost, reduce the aspects such as environmental pollution and all have positive role, there is the unrivaled superiority of traditional method.
The present invention easily understands for those skilled in the art; the foregoing is only preferred embodiment of the present invention; not in order to limit the present invention; any modification of doing within all the spirit and principles in the present invention, be equal to and replace and improvement etc., within all should being included in protection scope of the present invention.
Claims (6)
1. the concentrated production technology of Chinese medicine preparation anti-inflammatory and choleretic tablet raw material extracting solution, is characterized in that, this process comprises the steps:
S1, raw material alcohol extraction: the Herba Andrographis of same aliquot being mixed with Ramulus Et Folium Picrasmae and use concentration is twice of 80%～85% ethanol heating extraction, each extraction time is 2 hours, to the filtrate of twice filtration being merged, is concentrated after the extracting liquid filtering of each extraction, obtain solid content and be 0.1%～16% alcohol extract, standby;
S2, membrance separation: select the diffusion barrier that medicine activity component is had to a selective retention performance to carry out pre-concentration to the alcohol extract obtaining in S1, wherein, isolated permeate is the alcoholic solution in the alcohol extract in S1, after reclaiming remaining ethanol by vacuum distillation equipment again, pastille concentrated solution after holding back is condensed into thick paste, wherein, operative temperature during membrance separation is 3 ℃～80 ℃; Operating pressure is 0.1MPa～6.0MPa;
S3, raw material water extraction: get with Herba Andrographis and decoct with water secondary with the Herba Rabdosiae Lophanthoidis of aliquot, the decoction liquor that each decoction is obtained is filtered, and by filtrate merge, concentrated, obtain solid content and be 0.1%～16% aqueous extract, standby;
S4, the membrance separation of Herba Rabdosiae Lophanthoidis extracting solution: select diffusion barrier medicine activity component to selective retention performance, by membrane separation plant, aqueous extract is carried out to pre-concentration, wherein, isolated permeate is the water in the aqueous extract in S3, pastille concentrated solution after holding back is transferred to evaporation concentration equipment again, being concentrated into relative density is 1.20～1.25(55～60 ℃) mastic, the ethanol that adds the concentration 60%～70% of 5～8 times of mastic amounts, stir evenly, standing, filter, filtrate recycling ethanol, and be condensed into Herba Rabdosiae Lophanthoidis extractum, wherein, the operative temperature of membrance separation is 3 ℃～80 ℃, operating pressure is 0.1MPa～6.0MPa,
S5, tablet preparation: two kinds of thick pastes in S2 and S4 are merged, mix, are dried, granulation, dry, in flakes, sugar coating or film-coat, obtain in compacting.
2. the concentrated production technology of a kind of Chinese medicine preparation anti-inflammatory and choleretic tablet raw material extracting solution according to claim 1, it is characterized in that, in S2, alcohol extract is placed in the first membrane module that the first head tank is crossed First Heat Exchanger, the first cartridge filter and is provided with diffusion barrier through device for cleaning pipeline, permeate is stored in the first permeate storage tank, and pastille concentrated solution is stored in the first concentrated solution holding vessel.
3. the concentrated production technology of a kind of Chinese medicine preparation anti-inflammatory and choleretic tablet raw material extracting solution according to claim 1, it is characterized in that, in S4, the second membrane module that aqueous extract is placed in the second head tank and crosses the second heat exchanger, the second cartridge filter and be provided with diffusion barrier through device for cleaning pipeline, permeate is stored in the second permeate storage tank, and pastille concentrated solution is stored in the second concentrated solution holding vessel.
4. according to the concentrated production technology of a kind of Chinese medicine preparation anti-inflammatory and choleretic tablet raw material extracting solution described in claim 2 or 3, it is characterized in that, in step S2 and step S4, the kind of diffusion barrier is selected from ultrafilter membrane or NF membrane or reverse osmosis membrane, and the specification of diffusion barrier is molecular cut off >=200.
5. the concentrated production technology of a kind of Chinese medicine preparation anti-inflammatory and choleretic tablet raw material extracting solution according to claim 4, is characterized in that, in step S2 and step S4, the material of described diffusion barrier is selected from cellulose membrane or polysulfone membrane or polyamide membrane or ceramic membrane.
6. the concentrated production technology of Chinese medicine preparation anti-inflammatory and choleretic tablet raw material extracting solution according to claim 5, it is characterized in that the alcohol extract concentration in S1 is that solid content is 0.8%, what in S2, adopt is the low pressure reverse osmosis diffusion barrier in reverse osmosis membrane, operative temperature is that 36 ℃, operating pressure are 2.6MPa, aqueous extract concentration in S3 is solid content 1.1%, what in S4, adopt is the nanofiltration separation membrane of DL series, and operative temperature is that 36 ℃, operating pressure are 2.0Mpa.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310692048.9A CN103655649A (en) | 2013-12-10 | 2013-12-10 | Production technology for concentrating raw material extract of traditional Chinese medicine preparation of anti-inflammation and cholagogic tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310692048.9A CN103655649A (en) | 2013-12-10 | 2013-12-10 | Production technology for concentrating raw material extract of traditional Chinese medicine preparation of anti-inflammation and cholagogic tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103655649A true CN103655649A (en) | 2014-03-26 |
Family
ID=50295209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310692048.9A Pending CN103655649A (en) | 2013-12-10 | 2013-12-10 | Production technology for concentrating raw material extract of traditional Chinese medicine preparation of anti-inflammation and cholagogic tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103655649A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105289308A (en) * | 2015-11-19 | 2016-02-03 | 安徽元通水处理设备有限公司 | Equipment for traditional Chinese medicine purification and applications thereof |
| CN105738270A (en) * | 2016-02-16 | 2016-07-06 | 杭州水处理技术研究开发中心有限公司 | Detection method for acid and alkali resistance of reverse osmosis membrane |
| CN110585007A (en) * | 2019-09-10 | 2019-12-20 | 苏州市天灵中药饮片有限公司 | High-efficiency concentration process of traditional Chinese medicine extracting solution |
-
2013
- 2013-12-10 CN CN201310692048.9A patent/CN103655649A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 国家药典委员会: "《中华人民共和国药典：2010年版 一部》", 31 January 2010, 中国医药科技出版社 * |
| 孙体昌: "《固液分离》", 31 August 2011, 中南大学出版社 * |
| 郭维图: "膜分离技术在中药提取液浓缩中的应用", 《机电信息》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105289308A (en) * | 2015-11-19 | 2016-02-03 | 安徽元通水处理设备有限公司 | Equipment for traditional Chinese medicine purification and applications thereof |
| CN105738270A (en) * | 2016-02-16 | 2016-07-06 | 杭州水处理技术研究开发中心有限公司 | Detection method for acid and alkali resistance of reverse osmosis membrane |
| CN110585007A (en) * | 2019-09-10 | 2019-12-20 | 苏州市天灵中药饮片有限公司 | High-efficiency concentration process of traditional Chinese medicine extracting solution |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1995007B (en) | Process for preparing rosmarinic acid | |
| CN101564407B (en) | Process for refining isatis root extract by applying membrane separation technique | |
| CN102232977A (en) | Method for extracting total saponins from pokeberry root | |
| CN105949185B (en) | Kwangsi stephania root prepares rotundin hydrochloride method | |
| CN102198049A (en) | Traditional Chinese medicine preparation method and device | |
| CN103655649A (en) | Production technology for concentrating raw material extract of traditional Chinese medicine preparation of anti-inflammation and cholagogic tablet | |
| CN104292281B (en) | A kind of integrated technology prepares the method for high-purity rutoside | |
| CN103655655A (en) | Method for separating active ingredients from medicinal material by membrane technology | |
| CN102258659A (en) | Method for preparing ageratum oral liquid | |
| CN101559090A (en) | Extracting method of steroid saponins of yerbadetajo | |
| CN102302548B (en) | Preparation method for compound salvia tablets | |
| CN1935965B (en) | Refined volatile oil and its preparing method | |
| CN105326055B (en) | A kind of plum halogen essence functional food rich in aldehydes matter and organic acid and preparation method thereof | |
| CN104189087B (en) | A kind of method extracting total flavonoid functional materials from Folium Mori | |
| CN105669386A (en) | Method for separating and concentrating resveratrol from peanut root extracting solution | |
| CN102247436B (en) | Preparation method of Qingxuanpian | |
| CN101792394A (en) | Extraction separation method of L-synephrine | |
| CN102462817A (en) | Preparation method of rhizoma arundinis alkaloid | |
| CN103962007B (en) | A kind of automatic programme control supersonic jet uniform filtration device | |
| CN102114063B (en) | Method for extracting and separating asiaticoside by countercurrent extraction combined with membrane separation | |
| CN102293973A (en) | Preparation method of cough-relieving tablets | |
| CN102293812B (en) | Preparation method of stranguria-treating and calculus-removing particles | |
| CN204093314U (en) | Chinese traditional medicine purification reverse osmosis membrane filtration system | |
| CN105111257B (en) | It is a kind of to prepare glucose acetyl vanilla glycosides, the process of 10 fragrant pod acyl Catalpols and the trans cinnamyl Catalpols of 6 ' O simultaneously | |
| CN103265472A (en) | Method for separating 5-hydroxy tryptophan from griffonia simplicifolia seed extractive crystallization mother liquor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140326 |
|
| WD01 | Invention patent application deemed withdrawn after publication |